| Source: |
| Type: |
| Transglutaminase 2 is usually abbreviated TG2, also called tissue transglutaminase or TGM2 for the gene. In cancer biology, TG2 is generally treated as a pro-cancer survival, EMT, invasion, metastasis, cancer stemness, and therapy-resistance factor, although its effect can be context-dependent by cancer type, subcellular location, and enzymatic vs non-enzymatic/scaffold function. Recent reviews emphasize TG2 as a major driver of EMT, metastasis, drug resistance, and cancer-cell survival signaling.
| Field | Entry |
| ----------------- | -------------------------------------------------------------------------------- |
| Target / pathway | Transglutaminase 2 |
| Abbrev. | TG2 |
| Gene | TGM2 |
| Cancer direction | Usually upregulated / activated in aggressive, invasive, metastatic,
and drug-resistant cancers |
| Cancer effect | Mostly pro-cancer |
| Best cancer label | EMT / metastasis / chemoresistance / cancer stemness / NF-κB survival signaling |
| Therapeutic logic | TG2 inhibition or knockdown is usually expected to reduce invasion, EMT,
survival, stem-like traits, and drug resistance |
| Caution | TG2 is multifunctional and can have context-specific effects; extracellular TG2,
intracellular TG2, catalytic activity, GTP-binding/scaffold activity,
and cancer type matter |
|
| 6264- | Cyste, | Different inhibition characteristics of intracellular transglutaminase activity by cystamine and cysteamine |
| - | Review, | Nor, | NA |
| 6263- | Cyste, | Mechanism for the inhibition of transglutaminase 2 by cystamine |
| - | Study, | Nor, | NA |
| 6259- | Cyste, | Therapeutic Applications of Cysteamine and Cystamine in Neurodegenerative and Neuropsychiatric Diseases |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 6258- | Cyste, | Cystamine and cysteamine as inhibitors of transglutaminase activity in vivo |
| - | Review, | NA, | NA |
| 6256- | Cyste, | Transglutaminase 2 expression levels regulate sensitivity to cystamine plus TRAIL-mediated apoptosis |
| - | in-vitro, | Kidney, | Caki-1 |
| 4331- | Cyste, | Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase |
| - | in-vivo, | HD, | NA | - | NA, | AD, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1475 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid